Systemic sclerosis (SSc) is a chronic disorder, characterized by autoimmunity, inflammation, functional and then structural abnormalities of micro vessels and, finally, widespread interstitial and vascular fibrosis involving skin and internal organs [1]. Based on clinical features and the presence of specific SSc-related autoantibodies, the following forms of SSc have been described: limited SSc (lcSSc), diffuse SSc (dcSSc) and SSc without skin involvement [2].Cardiac involvement in SSc can be primary, direct consequence of this disease or secondary, associated with SSc pulmonary hypertension or renal crisis [3]. The clinical features of SSc heart involvement are highly variable, from silent forms to heart failure. Based on this fact, the prevalence of SSc cardiac involvement varies greatly, from 10% to 50%, depending on the diagnostic method used (clinical exam, electrocardiography, cardiac ultrasonography, cardiac magnetic resonance imaging) [4]. The rapid skin thickness progression is associated with higher cardiac involvement. Cardiac causes represent 20% to 36% of deaths associated with SSc. Several mechanisms are involved in SSc heart disease: microvascular alterations, myocardial inflammation, fibrosis and autonomic dysfunction [1,2,5].Electrocardiographic abnormal findings are identified in 25-75% of SSc patients, being represented by: atrial and ventricular tachyarrhythmias, conduction abnormalities and bradyarrhythmias. They are considered to be an independent predictor of mortality [6]. In SSc, even without cardiac symptoms, QT and corrected QT (QTc) intervals appear prolonged, which can lead to life-threatening tachyarrhythmias [7].